Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.01
BDSI's Cash-to-Debt is ranked lower than
81% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. BDSI: 1.01 )
Ranked among companies with meaningful Cash-to-Debt only.
BDSI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 6.06 Max: No Debt
Current: 1.01
Equity-to-Asset 0.36
BDSI's Equity-to-Asset is ranked lower than
81% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BDSI: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
BDSI' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.52  Med: 0.35 Max: 0.87
Current: 0.36
-2.52
0.87
Piotroski F-Score: 2
Altman Z-Score: -1.67
Beneish M-Score: 2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -90.73
BDSI's Operating Margin % is ranked higher than
51% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. BDSI: -90.73 )
Ranked among companies with meaningful Operating Margin % only.
BDSI' s Operating Margin % Range Over the Past 10 Years
Min: -10722.77  Med: -445.27 Max: 63.88
Current: -90.73
-10722.77
63.88
Net Margin % -0.19
BDSI's Net Margin % is ranked higher than
70% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. BDSI: -0.19 )
Ranked among companies with meaningful Net Margin % only.
BDSI' s Net Margin % Range Over the Past 10 Years
Min: -12468.81  Med: -260.99 Max: 6552.47
Current: -0.19
-12468.81
6552.47
ROE % -0.95
BDSI's ROE % is ranked higher than
75% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. BDSI: -0.95 )
Ranked among companies with meaningful ROE % only.
BDSI' s ROE % Range Over the Past 10 Years
Min: -957  Med: -202.37 Max: 6.13
Current: -0.95
-957
6.13
ROA % -0.10
BDSI's ROA % is ranked higher than
77% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. BDSI: -0.10 )
Ranked among companies with meaningful ROA % only.
BDSI' s ROA % Range Over the Past 10 Years
Min: -133.16  Med: -60.42 Max: 124.67
Current: -0.1
-133.16
124.67
ROC (Joel Greenblatt) % -875.91
BDSI's ROC (Joel Greenblatt) % is ranked lower than
60% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. BDSI: -875.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BDSI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10265.14  Med: -991.94 Max: 2073.85
Current: -875.91
-10265.14
2073.85
3-Year Revenue Growth Rate -1.00
BDSI's 3-Year Revenue Growth Rate is ranked lower than
58% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BDSI: -1.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BDSI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -64.8  Med: 12.85 Max: 418.2
Current: -1
-64.8
418.2
3-Year EBITDA Growth Rate -7.10
BDSI's 3-Year EBITDA Growth Rate is ranked lower than
60% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. BDSI: -7.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BDSI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.3  Med: -1.85 Max: 53.4
Current: -7.1
-47.3
53.4
3-Year EPS without NRI Growth Rate -6.10
BDSI's 3-Year EPS without NRI Growth Rate is ranked lower than
56% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. BDSI: -6.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BDSI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.1  Med: 16.8 Max: 68.4
Current: -6.1
-68.1
68.4
GuruFocus has detected 5 Warning Signs with BioDelivery Sciences International Inc $BDSI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BDSI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:PHGUF, NAS:SVRA, NAS:CBAY, NAS:CDXC, OTCPK:SPRWF, OTCPK:PRMCF, AMEX:OCX, NAS:MDWD, NAS:KURA, NAS:VTVT, NAS:GNCA, NAS:RDHL, NAS:PPHM, NAS:ALBO, AMEX:XXII, NAS:VBIV, NAS:ATHX, NAS:FOMX, NAS:CNAT, NAS:MNKD » details
Traded in other countries:BD5.Germany,
Headquarter Location:USA
BioDelivery Sciences International Inc is a specialty pharmaceutical company. It is developing and commercializing new applications of approved therapeutics to address important unmet medical needs.

BioDelivery Sciences International is a biotechnology company that specializes in pain management and addiction medicine. The company's products and candidates are based on BioErodible MucoAdhesive, a proprietary B drug delivery technology. BEMA is a small, erodible polymer film for application to the buccal mucosa, which is used in approved products and candidates such as ONSOLIS (fentanyl buccal soluble film) for treating cancer pain; BUNAVAIL (buprenorphine and naloxone buccal film) to treat opioid dependence; and product candidate BELBUCA (formerly referred to as BEMA Buprenorphine), which aims to treat chronic pain.

Ratios

vs
industry
vs
history
Forward PE Ratio 14.37
BDSI's Forward PE Ratio is ranked higher than
68% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 22.68 vs. BDSI: 14.37 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 4.16
BDSI's PB Ratio is ranked lower than
52% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. BDSI: 4.16 )
Ranked among companies with meaningful PB Ratio only.
BDSI' s PB Ratio Range Over the Past 10 Years
Min: 2.3  Med: 6.68 Max: 354.74
Current: 4.16
2.3
354.74
PS Ratio 3.81
BDSI's PS Ratio is ranked higher than
75% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. BDSI: 3.81 )
Ranked among companies with meaningful PS Ratio only.
BDSI' s PS Ratio Range Over the Past 10 Years
Min: 0.89  Med: 16.21 Max: 1156.67
Current: 3.81
0.89
1156.67
Current Ratio 1.78
BDSI's Current Ratio is ranked lower than
78% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BDSI: 1.78 )
Ranked among companies with meaningful Current Ratio only.
BDSI' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 1.2 Max: 6.96
Current: 1.78
0.03
6.96
Quick Ratio 1.52
BDSI's Quick Ratio is ranked lower than
76% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BDSI: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
BDSI' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 1.2 Max: 6.96
Current: 1.52
0.03
6.96
Days Inventory 126.02
BDSI's Days Inventory is ranked higher than
52% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. BDSI: 126.02 )
Ranked among companies with meaningful Days Inventory only.
BDSI' s Days Inventory Range Over the Past 10 Years
Min: 67.55  Med: 96.06 Max: 126.02
Current: 126.02
67.55
126.02
Days Sales Outstanding 61.74
BDSI's Days Sales Outstanding is ranked higher than
53% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. BDSI: 61.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
BDSI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.49  Med: 48.65 Max: 650.89
Current: 61.74
3.49
650.89
Days Payable 314.85
BDSI's Days Payable is ranked higher than
89% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. BDSI: 314.85 )
Ranked among companies with meaningful Days Payable only.
BDSI' s Days Payable Range Over the Past 10 Years
Min: 304.66  Med: 564.49 Max: 1275.75
Current: 314.85
304.66
1275.75

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.30
BDSI's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. BDSI: -12.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BDSI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.1  Med: -18 Max: -8
Current: -12.3
-38.1
-8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.23
BDSI's Price-to-Median-PS-Value is ranked higher than
91% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BDSI: 0.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BDSI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06  Med: 0.8 Max: 66.8
Current: 0.23
0.06
66.8
Earnings Yield (Greenblatt) % -23.80
BDSI's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. BDSI: -23.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BDSI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -256.7  Med: -25.9 Max: 148
Current: -23.8
-256.7
148

More Statistics

Revenue (TTM) (Mil) $41.98
EPS (TTM) $ -0.03
Beta1.27
Short Percentage of Float7.89%
52-Week Range $1.50 - 3.10
Shares Outstanding (Mil)55.33

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 54 46 74
EPS ($) 0.20 -0.62 -0.30
EPS without NRI ($) 0.20 -0.62 -0.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BDSI

Headlines

Articles On GuruFocus.com
BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA® and BUNAVAIL® Through 2020 Jun 21 2017 
BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair 20 Jun 01 2017 
/C O R R E C T I O N -- BioDelivery Sciences International, Inc./ May 15 2017 
BioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides Corporate Update May 15 2017 
BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial Resu May 09 2017 
BioDelivery Sciences Announces the Approval of BUNAVAIL® for Induction of Buprenorphine Treatment f May 02 2017 
BioDelivery Sciences to Present at the Deutsche Bank 42nd Annual Health Care Conference Apr 26 2017 
BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Fur Mar 31 2017 
Weekly CFO Buys Highlight: BioDelivery Sciences International, TheStreet, Antares Pharma Mar 27 2016 
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 

More From Other Websites
Raleigh's BDSI expands international distribution of Belbuca Jun 23 2017
BioDelivery Sciences Announces Health Canada Approval of BELBUCA® Jun 23 2017
ETFs with exposure to BioDelivery Sciences International, Inc. : June 22, 2017 Jun 22 2017
BioDelivery Inks New Contract with CVS/Caremark, Shares Up Jun 22 2017
Raleigh's BDSI lands CVS/Caremark contract Jun 21 2017
BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA® and BUNAVAIL® Through 2020 Jun 21 2017
BioDelivery Sciences (BDSI) Up 16.7% Since Earnings Report: Can It Continue? Jun 15 2017
BioDelivery Sciences International, Inc. :BDSI-US: Earnings Analysis: Q1, 2017 By the Numbers : June... Jun 14 2017
BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair... Jun 01 2017
Today's Research Reports on Stocks to Watch: BioDelivery Sciences International and Zosano Pharma May 30 2017
Edited Transcript of BDSI earnings conference call or presentation 15-May-17 8:30pm GMT May 21 2017
BioDelivery Sciences International (BDSI) Jumps: Stock Up 5% May 18 2017
BDSI CEO on Belbuca revenue potential: We're on an upward trend May 16 2017
BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains May 16 2017
/C O R R E C T I O N -- BioDelivery Sciences International, Inc./ May 15 2017
BioDelivery tops Street 1Q forecasts May 15 2017
Investor Network: BioDelivery Sciences International, Inc. to Host Earnings Call May 15 2017
BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial... May 09 2017
What's in Store for BioDelivery (BDSI) this Earnings Season? May 08 2017
BDSI's expanded approval of opioid dependence drug required few resources, exec says May 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}